CREATING NEXT GENERATION RNA THERAPIES
Advancing Next-Generation RNA Therapeutics
Vaxeleron is redefining RNA-based medicine with its proprietary trans-amplifying RNA replicon platform, enabling potent therapeutics and vaccines at low doses.
This technology drives sustained protein expression from minimal RNA, reducing formulation needs while boosting impact. We are applying it across a wide range of RNA therapeutics to unlock new possibilities in precision medicine.
Driven by Purpose, Committed to Impact
Our proprietary platform has been designed to enable personalized cancer care with RNA-based therapies that address unmet medical needs in oncology and beyond. We see our business success as a direct reflection of the value we create—from patient-specific therapies that target individual tumor profiles to transformative treatments that redefine standards of care.
We are partnering with major industry leaders developing next-generation RNA therapies tailored to each patient, driving the future of precision medicine.
Our Technology
Our technology is based on an innovative trans-amplifying RNA (taRNA) platform that enables RNA to self-amplify within the patient’s own cells. Our approach separates the replicase machinery from the therapeutic payload. Once the taRNA is inside the cell, the replicase amplifies the payload RNA, driving high and sustained antigen expression from minimal RNA input. Using this proprietary split-replicon design, we unlock potent RNA therapies at lower doses—reducing safety risks while maximizing efficacy.
OUR LEADERSHIP TEAM
EXPERIENCED LEADERSHIP
Konrad Stadler
CEO and CSO
Konrad is a co-founder, CEO and CSO at Vaxeleron, bringing over 20 years of experience in human and veterinary biopharmaceutical R&D, with a strong focus and passion for innovative vaccine solutions...
Prior to founding Vaxeleron, he served as CSO at Viroclinics-DDL and led the vaccine program at the German Center for Infectious Disease Research. His career also includes key roles as Global Head of R&D for Swine Vaccines at Ceva Santé Animale, General Manager of the Ceva Innovation Center in Dessau, Germany, and Head of Animal Vaccine R&D, EU at Boehringer Ingelheim. Additionally, he was Head of Molecular Microbiology at the International Vaccine Institute in Seoul, South Korea, and previously worked as a senior scientist at Chiron Vaccines and Novartis Vaccines in Siena, Italy. Konrad holds a doctoral degree in biochemistry from the University of Vienna, Austria
Melanie Sno
MD and COO
Randolph Seidler
Consultant
Randolph is a co-founder and consultant and has extensive R&D and portfolio leadership experience...
As Head of Global R&D and Regulatory Affairs for 10 years at Boehringer Ingelheim Animal Health (BIAH), he oversaw the global research, development and registration of multiple highly innovative drugs and vaccines. During this time BIAH brought multiple new molecular entities (vaccines and pharmaceuticals) to all major markets.
During his career he also held the position of Global Head of Business Development, Licensing and Alliance Management, where he oversaw the successful negotiation of several joint ventures, technology licenses and equity investments. Prior to this he held various international positions of growing responsibility within Boehringer Ingelheim’s human pharma R&D organization, including roles in cardiovascular diseases in the US and in Germany.
In addition to his role in Vaxeleron, Randolph supports several animal health startup companies through supervisory and advisory board positions. Randolph holds a degree in Veterinary Medicine and a Doctorate in physiology from the Ludwig-Maximilians-University in Munich, Germany and an Executive MBA from INSEAD in Fontainebleau, France.
Gianclaudio Antonelli
Consultant
Gianclaudio is a co-founder of Vaxeleron and is currently serving as consultant regarding administration, finance and legal...
In this function he had a key role in securing the research funding from R3 Wellcome Leap. He is also serving as managing director of our Italian affiliate company Veterna srl. Prior to Vaxeleron, he served as CFO for the Italian start-up Contraria Biotech (formerly Achilles Vaccines) where he was instrumental in the negotiation and implementation its first two rounds of seed financing which, at the time, was the largest ever in Italy.
SCIENTIFIC ADVISORY BOARD
Sir Michael Houghton
Nobel Laureate Sir Michael Houghton is the Li Ka Shing Professor of Virology at the University of Alberta and Director of the Li Ka Shing Applied Virology Institute. He was jointly awarded the 2020 Nobel Prize in Physiology or Medicine, together with Harvey J. Alter and Charles M. Rice, for the discovery of hepatitis C virus (HCV), and was knighted by Queen Elizabeth II in 2020 for services to medicine.
Born in the United Kingdom, Dr. Houghton obtained a BSc in biological sciences from the University of East Anglia and a PhD in biochemistry from King’s College London. He began his career at G.D. Searle & Company in the UK before joining Chiron Corporation in California, where, together with colleagues Qui-Lim Choo and George Kuo, and Daniel W. Bradley from the U.S. Centers for Disease Control and Prevention, he first identified HCV in 1989. He authored seminal studies that led to the blood screening tests introduced in the early 1990s, which eliminated hepatitis C contamination from donated blood supplies worldwide, and identified key viral replication enzymes that became critical targets for today’s highly effective antiviral therapies.
Albert Osterhaus
Professor Ab Osterhaus served as Head of the Department of Viroscience at Erasmus MC in Rotterdam until 2014 and is currently Director of the Center of Infection Medicine and Zoonosis Research and Guest Professor at the University of Veterinary Medicine, Hannover. He has an extensive track record as a scientific researcher and Principal Investigator of numerous major projects, pioneering an integrated “viroscience” approach bringing together world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention studies on human and animal virus infections.
Professor Osterhaus has discovered multiple new human and animal viruses, including the human metapneumovirus, influenza and coronaviruses, and has elucidated the pathogenesis of major viral infections while developing novel intervention strategies. This work has enabled health authorities such as the WHO to more effectively combat outbreaks including SARS and avian influenza. He has supervised over 80 PhD students, holds several key patents, and has authored more than 1,300 peer-reviewed publications. His international standing is reflected in major scientific awards, invited lectureships, membership in the Dutch and German National Academies of Sciences, and the Belgian Academy of Medicine, and his appointment as Commander of the Order of the Dutch Lion.
Geert Leroux-Roels
Professor Geert Leroux-Roels received his MD from Ghent University in 1976. During his medical studies and specialization in internal medicine, he conducted doctoral research in clinical pathology and immunology. After obtaining board certification in internal medicine and...
a PhD in biomedical sciences, he completed postdoctoral research at the Scripps Research Institute in La Jolla, California, and at the Laboratory of Molecular Biology at Ghent University. In 1989, he was appointed professor of medicine and director of the Laboratory of Clinical Pathology.
For over 30 years, Dr. Leroux-Roels and his team have focused on the human immune response to HBV, HCV, HIV, malaria and influenza. They developed a small animal model (human liver in uPA-SCID mice), enabling in vivo studies of hepatotropic pathogens such as HBV, HCV, HEV, and Plasmodium falciparum (malaria).
Dr. Leroux-Roels founded the Center for Vaccinology (CEVAC) at Ghent University and Ghent University Hospital, directing the unit for three decades. Under his leadership, over 275 clinical vaccine trials were conducted, evaluating a wide array of candidate vaccines (HAV, HBV, [HAV+HBV], HSV, HPV, HIV, TB, malaria) and new adjuvant systems.
He is the author or co-author of 320 peer-reviewed articles and is an active member of several international societies and scientific advisory boards
Alan Liss
Dr. Alan Liss has over 35 years of experience in the areas of vaccines, plasma products, and biologics product development and manufacturing. Alan has held a variety of industry and academic appointments, authored over 60 scientific publications. He received a Bachelor of Science degree in Genetics from the University of California, Berkeley in 1969, and his Ph.D. in Microbiology and Immunology from the University of Rochester, School of Medicine and Dentistry in 1974. Alan retired from FDA where he directed the Public Health and Security Action Team Program within the Office of the Commissioner. Alan has lectured globally in the areas of using effective quality and compliance programs needed to enhance product development and manufacturing and on the fundamental principles needed for effective engagement with FDA throughout the product development process. Alan and the GXP farma team currently focus on the growing vaccine and biopharma industries located outside of the continental USA.